At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 187 enrolled
Drug / intervention
Retigabine +1 moredrug
Likely dose
Retigabine 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated With Post-Herpetic Neuralgia
In Brief
A Phase 2 clinical trial evaluating Retigabine and Placebo for Postherpetic Neuralgia. Completed, enrolled 187 participants across 45 sites in 2 countries.
Detailed Summary
The purpose of the study is to evaluate the efficacy of retigabine vs. placebo in reducing pain associated with post-herpetic neuralgia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostherpetic Neuralgia
CountriesSouth Africa, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedFeb 2008
Primary CompletionMay 2009
Study CompletionDec 2009
TodayJul 2026
First PostedFeb 11, 2008
Enrollment StartOct 1, 2007
Primary CompletionMay 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 18.4 years ago
Interventions
Retigabinedrug
150mg/day up to 900mg/day
Placebodrug
daily